Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.
Follow COGT
Cogent Biosciences, Inc. (COGT) EV/Sales
As of 16 October 2026, Cogent Biosciences, Inc. (COGT) trades at a EV/Sales of 193×. Over the past ten years it has ranged from −6.7× (March 2021) to 292× (August 2026); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | −4.9× | — |
| FY2019 | −0.5× | — |
| FY2018 | 3.2× | (63.11%) |
| FY2017 | 8.6× | 0.00% |
| FY2016 | 8.6× | 0.00% |
| FY2015 | 8.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2020 | 4.5× | — |
| Jun 2020 | −0.1× | — |
| Mar 2020 | −0.5× | — |
| Dec 2019 | −0.5× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| TVTX Travere Therapeutics, Inc. compare | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| SRRK Scholar Rock Holding Corporation compare | 104× |
| COGT Cogent Biosciences, Inc. | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| CGON CG Oncology, Inc. compare | 684× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)